[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Sousa-Escandon A, Vazquez S, Quintero-Aldana G, Picallo JA, Neira J, Garcia-Novio F, Mateo A, Rico M, Mel JR: Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: a phase II trial. Int J Urol; 2002 Mar;9(3):162-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: a phase II trial.
  • BACKGROUND: A phase II multicentric trial of paclitaxel and cisplatin was conducted in previously untreated patients, with locally advanced transitional-cell carcinoma (TCC) of the bladder, to assess its toxicity and efficiency in preserving the bladder.
  • METHODS: Forty-four patients with locally advanced TCC of the bladder (seven with T3a, 27 with T3b, and eight with T4a) were treated with paclitaxel 175 mg/m(2) over 3 h, and cisplatin 75 mg/m(2) over 30 min, on the first day of each 21-day treatment cycle.
  • Therapy was continued for three cycles.
  • Tumoral response was measured by citology, computed tomographical scans, and deep randomized biopsies of the bladder.
  • Response times ranged from 18 to 54 months.
  • Three patients with T4 bladder primary tumors experienced a pathological CR.
  • Drug omissions or dose delay for adverse events were only necessary in one patient (2.2%), and three patients (6.8%), respectively.
  • CONCLUSIONS: Paclitaxel and cisplatin is an active and well-tolerated neo-adjuvant regimen for previously untreated patients with pure TCC of the bladder, achieving a vesical preservation rate of 52%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Anemia / chemically induced. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Nausea / chemically induced. Neoadjuvant Therapy. Paclitaxel / administration & dosage. Thrombocytopenia / chemically induced

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12010328.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Dhawan D, Craig BA, Cheng L, Snyder PW, Mohammed SI, Stewart JC, Zheng R, Loman RA, Foster RS, Knapp DW: Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol Cancer Ther; 2010 May;9(5):1371-7
Hazardous Substances Data Bank. CELECOXIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder.
  • High-grade invasive transitional cell carcinoma (InvTCC) kills >14,000 people yearly in the United States, and better therapy is needed.
  • Cyclooxygenase-2 (Cox-2) is overexpressed in bladder cancer.
  • The main study end point was induction of apoptosis in tumor tissues.
  • Patients received celecoxib (400 mg twice daily p.o. for a minimum of 14 days) between the time of diagnosis [transurethral resection of bladder tumor (TURBT)] and the time of cystectomy (standard frontline treatment for InvTCC).
  • Of 13 cases treated with celecoxib, no residual invasive cancer was identified in 3 patients at the time of cystectomy (post celecoxib).
  • The biological effects of celecoxib treatment (increased apoptosis) justify further study of the antitumor effects of Cox-2 inhibitors in InvTCC.

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2005 Apr 15;103(8):1685-92 [15742356.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;46(3):221-6 [11021739.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):800-6 [16467091.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):329-36 [16505106.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6649-56 [16818638.001]
  • [Cites] J Surg Oncol. 2006 Sep 1;94(3):226-33 [16900533.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jan;61(1):52-69 [16945549.001]
  • [Cites] Cancer Lett. 2007 Jun 8;250(2):177-93 [17084966.001]
  • [Cites] Cancer Biol Ther. 2007 Feb;6(2):269-75 [17224647.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):5999-6002 [17616652.001]
  • [Cites] J Biol Chem. 2008 Feb 8;283(6):3289-96 [18057009.001]
  • [Cites] Mol Cancer Ther. 2008 Apr;7(4):897-904 [18413803.001]
  • [Cites] Mod Pathol. 2008 Jun;21(6):764-9 [18425079.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5000-5 [18698017.001]
  • [Cites] Oncogene. 2008 Oct 20;27(48):6276-84 [18931693.001]
  • [Cites] Eur Respir J. 2009 Jan;33(1):127-33 [18715879.001]
  • [Cites] Tumori. 2006 Mar-Apr;92(2):130-3 [16724692.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):465-73 [16728574.001]
  • [Cites] World J Gastroenterol. 2006 Jun 7;12(21):3425-9 [16733863.001]
  • [Cites] Jpn J Clin Oncol. 2006 May;36(5):263-8 [16735371.001]
  • [Cites] Mol Cancer. 2006;5:19 [16707021.001]
  • [Cites] BMC Cancer. 2006;6:134 [16712734.001]
  • [Cites] Science. 2001 Nov 30;294(5548):1871-5 [11729303.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):356-8 [11809678.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27613-21 [12000750.001]
  • [Cites] FASEB J. 2003 Aug;17(11):1547-9 [12824303.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2030-8 [15026340.001]
  • [Cites] Brain Res Mol Brain Res. 2004 Jun 18;125(1-2):113-9 [15193428.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4281-4 [7913874.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 1999 Mar;28(3 Suppl):13-8 [10193998.001]
  • [Cites] Ann Pharmacother. 1999 Sep;33(9):979-88 [10492503.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):803-10 [15499625.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):153-60 [15272284.001]
  • [Cites] Int J Urol. 2005 Feb;12(2):152-8 [15733109.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Apr;2(4):285-7 [19336723.001]
  • [Cites] Cancer Genomics Proteomics. 2009 Mar-Apr;6(2):93-9 [19451093.001]
  • [Cites] Clin Cancer Res. 2009 Aug 1;15(15):4954-62 [19622584.001]
  • [Cites] J Urol. 2006 Jun;175(6):2058-62 [16697803.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5647-50 [10582676.001]
  • [Cites] Oncogene. 1999 Dec 20;18(55):7908-16 [10630643.001]
  • [Cites] J Clin Pharmacol. 2000 Feb;40(2):124-32 [10664917.001]
  • [Cites] Acta Otolaryngol. 2006 Feb;126(2):197-203 [16428200.001]
  • (PMID = 20423998.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093011-02; United States / NCI NIH HHS / CA / R21 CA093011; United States / NCI NIH HHS / CA / R21 CA093011-02; United States / NCI NIH HHS / CA / R21 CA93011
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib
  • [Other-IDs] NLM/ NIHMS188489; NLM/ PMC2868069
  •  go-up   go-down


3. Hirai K, Sano H, Kita K, Mikata K, Ueki T, Fujikawa N, Kitami K, Hirokawa S: [Small cell carcinoma of the bladder: a case report]. Hinyokika Kiyo; 2005 Sep;51(9):635-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell carcinoma of the bladder: a case report].
  • Ultrasonography, magnetic resonance imaging and cystoscopy revealed a nodular invasive tumor in urinary bladder.
  • The histopathological findings of transurethral-biopsy specimen was the small cell carcinoma and transitional cell carcinoma of the bladder infiltrating into smooth muscle layer.
  • Total cystectomy with ileal conduit was performed following 1 course of neoadjuvant chemotherapy (M-VAC).
  • Computed tomography (CT) before adjuvant chemotherapy revealed tiny lung metastasis in left peripheral lung area.
  • As postoperative adjuvant therapy, 4 courses of chemotherapy (etoposide and calboplatin) were performed with 50 Gy of extra beam radiotherapy to the lung metastasis.
  • Follow up CT revealed disapperance of lung metastasis, and the patient has been free from disease for one year after chemotherapy.
  • [MeSH-major] Carcinoma, Small Cell / secondary. Carcinoma, Transitional Cell / secondary. Cystectomy. Lung Neoplasms / secondary. Neoplasms, Multiple Primary. Urinary Bladder Neoplasms / pathology. Urinary Diversion
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16229379.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


Advertisement
4. Danesi DT, Arcangeli G, Cruciani E, Altavista P, Mecozzi A, Saracino B, Orefici F: Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results. Cancer; 2004 Dec 1;101(11):2540-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
  • BACKGROUND: Organ preservation has been investigated in patients with muscle-invasive bladder carcinoma over the past decades as an alternative to radical cystectomy.
  • The majority of studies reported that trimodal schedules, including transurethral resection of bladder tumor (TURB), radiotherapy (RT), and chemotherapy, are a feasible and safe organ-sparing approach without deferring the survival probability.
  • However, to the authors' knowledge the best combination of RT and chemotherapy has yet to be well defined.
  • The current study evaluated the long-term results of a schedule of concurrent cisplatin and 5-fluorouracil (5-FU) administered as protracted intravenous infusions (PVI) during hyperfractionated radiotherapy (HFRT) with organ-sparing intent in patients with infiltrating transitional cell carcinoma of the bladder (TCCB).
  • After a complete TURB and bladder mapping, 42 of 77 patients underwent 2 cycles of induction chemotherapy.
  • Six to 8 weeks after RCT, patient response was evaluated by computed tomography scan, urine cytology, and TURB.
  • For patients with residual or recurrent invasive tumor, salvage cystectomy was recommended.
  • The observed toxicity, mainly hematologic, was higher among the patients who received induction chemotherapy compared with the patients who did not receive induction chemotherapy, even though the difference was not statistically significant.
  • The 5-year overall, bladder-intact, tumor-specific, disease-free, and cystectomy-free survival rates for all 77 patients were 58.5%, 46.6%, 75.0%, 53.5%, and 76.1%, respectively.
  • CONCLUSIONS: Combined treatment appeared to provide high response rates and can be offered as an alternative option to radical cystectomy in selected patients who refuse or are unsuitable for surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystectomy. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Dose Fractionation. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Male. Middle Aged. Radiotherapy, Adjuvant. Treatment Outcome. Urethra / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society
  • [CommentIn] J Urol. 2005 Oct;174(4 Pt 1):1252-3 [16145384.001]
  • (PMID = 15481058.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Tatsura H, Ogawa K, Sakata T, Okamura T: A nested variant of transitional cell carcinoma of the urinary bladder: a case report. Jpn J Clin Oncol; 2001 Jun;31(6):287-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A nested variant of transitional cell carcinoma of the urinary bladder: a case report.
  • Nested variants of transitional cell carcinomas (TCC-NVs) are relatively rare neoplasms in the urinary bladder, but at least 25 cases have been described.
  • This disease is characterized by the pathological finding of irregular nests and/or tubules of transitional carcinoma cells infiltrating the lamina propria without involvement of the mucosal layer.
  • Since the prognosis of TCC-NV is generally poor, comprehensive chemotherapy was performed.
  • No changes were observed on computed tomography and the performance status (0) remained the same after 1 year, so the treatment was considered effective.
  • We conclude that open biopsy should be carried out without hesitation when bladder cancer is suspected, even if there are negative findings of repeated urinary cytology examination and/or endoscopic cold cup biopsy.
  • Diagnosis and treatment at an early stage should reduce the mortality of patients with TCC-Nvs.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11463809.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Mohammed SI, Bennett PF, Craig BA, Glickman NW, Mutsaers AJ, Snyder PW, Widmer WR, DeGortari AE, Bonney PL, Knapp DW: Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res; 2002 Jan 15;62(2):356-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
  • In this study, we determined the effects of the cox inhibitor, piroxicam, on tumor response, apoptotic index, proliferative index, cyclooxygenase-2 expression, prostaglandin E(2) concentration, tumor microvessel density, and urine basic fibroblast growth factor and vascular endothelial growth factor concentrations in pet dogs with naturally occurring invasive transitional cell carcinoma of the urinary bladder.
  • [MeSH-major] Apoptosis / drug effects. Carcinoma, Transitional Cell / drug therapy. Cyclooxygenase Inhibitors / pharmacology. Neovascularization, Pathologic / drug therapy. Piroxicam / pharmacology. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Animals. Cell Division / drug effects. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Dinoprostone / metabolism. Disease Models, Animal. Dogs. Endothelial Growth Factors / urine. Female. Fibroblast Growth Factor 2 / urine. Humans. Isoenzymes / antagonists & inhibitors. Isoenzymes / biosynthesis. Lymphokines / urine. Male. Membrane Proteins. Neoplasm Invasiveness. Prostaglandin-Endoperoxide Synthases / biosynthesis. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11809678.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Endothelial Growth Factors; 0 / Isoenzymes; 0 / Lymphokines; 0 / Membrane Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 103107-01-3 / Fibroblast Growth Factor 2; 13T4O6VMAM / Piroxicam; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


7. Cruz Guerra NA, del Valle Manteca A, Zamora Martínez T, Tarroc Blanco A: [Metacronous transitional cell carcinoma of the prostatic urethra in a patient with history of nephroureterectomy for upper urinary tract urothelial tumor]. Arch Esp Urol; 2004 Dec;57(10):1125-7
Genetic Alliance. consumer health - Transitional cell carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metacronous transitional cell carcinoma of the prostatic urethra in a patient with history of nephroureterectomy for upper urinary tract urothelial tumor].
  • [Transliterated title] Carcinoma transicional de uretra prostatica meta-crónico en paciente con antecedente de nefroureterectomía por tumor uroteual del tracto urinario superior.
  • OBJECTIVES: We report one case of Metacronous transitional cell carcinoma (TCC) of the prostatic urethra in a patient with history of left nephroureterectomy 22 years before for urothelial neoplasia of the upper urinary tract.
  • Cystourethroscopy showed irregular hyperemic lesions in the prostatic urethra, cold biopsy of which showed urothelial atypia.
  • Pathology report of fragments of a posterior transurethral resection (TUR) was compatible with high-grade superficial transitional cell neoplasia.
  • RESULTS: Pathologic report of new samples showed TCC infiltrating the prostatic stroma.
  • Chemotherapy did not achieve significant results.
  • CONCLUSIONS: We emphasize the notable metachronous character of the transitional cell carcinoma of the prostatic urethra with respect to the upper urinary tract TCC.
  • We also point out the metastasic capacity of these neoplasias, as well as the bad prognosis of those cases in which chemotherapy is not effective.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Neoplasms, Second Primary / diagnosis. Urethral Neoplasms / diagnosis
  • [MeSH-minor] Humans. Male. Middle Aged. Nephrectomy. Ureteral Neoplasms / surgery. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714851.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


8. Orsola A, Cecchini L, Raventós CX, Trilla E, Planas J, Landolfi S, de Torres I, Morote J: Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR. BJU Int; 2010 Jan;105(2):202-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR.
  • OBJECTIVE: To determine factors predictive of positive findings at the 3-month follow-up evaluation (after transurethral resection of bladder tumour [TUR] and bacille Calmette-Guérin [BCG] therapy) in patients with initial high-grade (HG)T1 bladder cancer, and to assess the depth of lamina propria (LP) invasion and effectiveness of BCG therapy.
  • PATIENTS AND METHODS: In all, 138 patients with initial HGT1-transitional cell carcinoma (TCC) were prospectively assigned, after TUR + BCG and according to depth of LP invasion, to a postBCG-TUR (T1b) or cystoscopy/cytology (T1a) at 3 months.
  • Tumour size and carcinoma in situ (CIS) were significantly associated with positive findings and present in 26% (36/138) of the patients.
  • The postBCG-TUR (T1b cases), was positive in 31% (25/80), including seven infiltrating tumours.
  • CONCLUSIONS: In initial HGT1-TCC, tumour size and CIS were predictive factors of positive findings at 3 months after the initial TUR + BCG therapy.
  • Patients with HGT1-TCC invading the LP (T1b TCC) had a seven times higher risk of a positive repeat TUR if the initial tumour was >3 cm and a five-fold increased risk if associated with CIS.
  • The repeat TUR after BCG therapy allowed confirmation of complete resection and pathological evaluation of the BCG response.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. BCG Vaccine / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / surgery. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Administration, Intravesical. Aged. Combined Modality Therapy. Cystoscopy / methods. Epidemiologic Methods. Female. Humans. Male. Neoplasm Metastasis. Prognosis. Reoperation. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19558557.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCG Vaccine
  •  go-up   go-down


9. Raghavan D: Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladder. Urol Oncol; 2003 Nov-Dec;21(6):468-74
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladder.
  • Invasive transitional cell bladder cancer is associated with occult metastasis.
  • Approximately 50% of patients with clinically localized, invasive bladder cancer ultimately die of their disease.
  • Systemic chemotherapy has been combined with radical cystectomy in an attempt to improve survival.
  • Initial randomized trials did not show a statistically significant survival benefit from systemic single agent chemotherapy.
  • More recently, two multi-center randomized trials have shown a significant survival benefit from neoadjuvant combination chemotherapy.
  • Adjuvant chemotherapy trials, to date, have failed to show statistically improved survival, although most published studies have been methodologically flawed.
  • For invasive, clinically nonmetastatic bladder cancer, neo-adjuvant chemotherapy followed by radical cystectomy is one of the new standards of care.
  • The role of postsurgical systemic chemotherapy appears promising, but has not been proven in a randomized trial.
  • Molecular prognostication is now being incorporated into the design of clinical trials of adjuvant chemotherapy for bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / surgery. Cystectomy. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14693275.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


10. Cobo M, Delgado R, Gil S, Herruzo I, Baena V, Carabante F, Moreno P, Ruiz JL, Bretón JJ, Del Rosal JM, Fuentes C, Moreno P, García E, Villar E, Contreras J, Alés I, Benavides M: Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer. Clin Transl Oncol; 2006 Dec;8(12):903-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer.
  • PURPOSE: Organ preservation has been investigated in patients (p) with infiltrating transitional cell carcinoma (TCC) of the bladder over the past decade as an alternative to radical cystectomy.
  • This is a trimodal schedule study, including transurethral resection of bladder tumor (TURB), neoadjuvant chemotherapy and concomitant radiochemotherapy (RTC).
  • PATIENTS AND METHODS: From April 1996 until August 2005, 29 evaluable patients (p) with T2-T3NXM0 bladder cancer were enrolled.
  • After a transurethral resection of bladder tumor (TURB), we administered 2 cycles of induction chemotherapy with CMV (15 p) or Gemcitabine-Cisplatin (14 p) followed by radiotherapy 45 Gy 1.8 Gy/fraction and two cycles of concomitant cisplatin 70 mg/m(2).
  • If complete histological response, p were treated with consolidation radiotherapy until 64.8 Gy.
  • Furthermore 14 of 29 p (48%) were alive with intact bladder, and median survival time with intact bladder was 63.6 m (50.1-77.2); were predictive of best outcome T2 stage vs T3 (p < 0.0001), and complete histologic resection in initial TURB vs residual tumor (p = 0.0004).
  • CONCLUSIONS: Combined treatment provide high response rates and can be offered as an alternative option to radical cystectomy in selected patients with TCC.
  • [MeSH-major] Antineoplastic Agents. Carcinoma, Transitional Cell / therapy. Neoadjuvant Therapy. Radiotherapy. Urinary Bladder Neoplasms / therapy. Urologic Surgical Procedures
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Kaplan-Meier Estimate. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Surg Oncol. 2001 Jan-Feb;20(1):24-32 [11291129.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):121-7 [9422567.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2540-8 [15481058.001]
  • [Cites] Curr Opin Urol. 2003 Sep;13(5):351-5 [12917510.001]
  • [Cites] J Urol. 2005 Jul;174(1):14-20 [15947569.001]
  • [Cites] J Urol. 1999 Aug;162(2):452-5; discussion 455-7 [10411055.001]
  • [Cites] Curr Opin Oncol. 1996 Jul;8(4):329-33 [8869809.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3061-71 [12118019.001]
  • [Cites] Lancet. 2003 Jun 7;361(9373):1927-34 [12801735.001]
  • [Cites] Urology. 1996 May;47(5):652-7 [8650861.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2564-9 [9215826.001]
  • [Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):89-93 [11134199.001]
  • [Cites] N Engl J Med. 2003 Aug 28;349(9):859-66 [12944571.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):273-8 [9607341.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] N Engl J Med. 1993 Nov 4;329(19):1377-82 [8413433.001]
  • [Cites] Urology. 2001 Jan;57(1):102-7 [11164152.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jun;34(6):295-306 [15333680.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):403-9 [10661347.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] Semin Surg Oncol. 2001 Apr-May;20(3):246-50 [11523110.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 May;17(3):160-6 [15900999.001]
  • [Cites] Cancer. 2003 Apr 15;97(8 Suppl):2115-9 [12673704.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1022-9 [9060542.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3576-83 [9817278.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):373-8 [10802362.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):119-26 [8558186.001]
  • [Cites] Br J Urol. 1997 Jul;80(1):44-9 [9240179.001]
  • (PMID = 17169764.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; MEC protocol 1
  •  go-up   go-down


11. Caffo O, Fellin G, Graffer U, Valduga F, Bolner A, Luciani L, Tomio L, Galligioni E: Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. Int J Radiat Oncol Biol Phys; 2003 Dec 1;57(5):1310-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer.
  • An improvement may be obtained by adding a new drug, such as gemcitabine, which is active in bladder cancer and acts as a radiosensitizer.
  • However, because gemcitabine may be very toxic when associated with radiotherapy, we designed this dose-finding study in an attempt to find the dose that can be safely added to radiotherapy and concurrent cisplatin in patients treated with transurethral resection for infiltrating bladder cancer.
  • PATIENTS AND METHODS: After undergoing macroscopically complete transurethral resections for transitional carcinoma of the bladder, patients staged pT2 or higher and without distant metastases concurrently received 54 Gy of fractionated radiotherapy over 6 weeks with cisplatin (100 mg/m(2) q.3 w), starting on Day 1 of radiotherapy.
  • Six to 8 weeks after completing the therapy, the patients underwent cystoscopic reevaluation with multiple biopsies of the initial tumor site.
  • At the dose 500 mg/m(2)/week, 1 patient experienced an intestinal perforation that recovered after surgery, and another suddenly died after developing Grade 3 untreated diarrhea in the last treatment week.
  • All of the 15 evaluable patients were microscopically disease free at the cystoscopic reevaluation; furthermore, the posttreatment computed tomography scans did not reveal any distant metastases.
  • CONCLUSIONS: After transurethral resection for the conservative treatment of infiltrating bladder cancer, gemcitabine doses of up to 400 mg/m(2)/week seem to be safe in combination with cisplatin and radiotherapy in organ-sparing management.
  • [MeSH-major] Carcinoma, Transitional Cell / radiotherapy. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Radiation-Sensitizing Agents / administration & dosage. Urinary Bladder Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Administration Schedule. Drug Therapy, Combination. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Quality of Life. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14630267.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Rübben H, Otto T: [Locally advanced or metastatic bladder carcinoma. Current aspects of therapy]. Urologe A; 2001 Nov;40(6):464-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Locally advanced or metastatic bladder carcinoma. Current aspects of therapy].
  • [Transliterated title] Lokal fortgeschrittenes oder metastasiertes Harnblasenkarzinom. Aktuelle Aspekte in der Therapie.
  • The prognostic factors for infiltrating tumors established by the TNM system in 1997 include: Depth of infiltration, degree of differentiation, status of lymph nodes distant metastases.
  • In the scope of molecular markers, the loss of expression of the epithelial cell-cell adhesion molecule E-cadherin signals an unfavorable clinical course.
  • In cases of carcinoma of the urinary bladder without metastases (T2-4,N0,M0), radical cystectomy is the therapy of choice.
  • A preceding neoadjuvant systemic regimen of chemotherapy with three cycles of M-VAC (methotrexate, vinblastine, adriamycin, cisplatin) significantly improves the survival rate.
  • In patients with locally advanced urinary bladder carcinoma, however, adjuvant systemic chemotherapy with M-VAC after cystectomy and lymphadenectomy offers no advantages for survival.
  • Quality of life in patients with metastatic bladder cancer disease is improved by new cytotoxic drugs, i.e. gemcitabine or taxanes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / surgery. Neoadjuvant Therapy. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Doxorubicin / administration & dosage. Humans. Lymph Node Excision. Methotrexate / administration & dosage. Neoplasm Invasiveness. Neoplasm Staging. Randomized Controlled Trials as Topic. Survival Rate. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11760352.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


13. Borrell Palanca A, Chicote Pérez F, Alcalá-Santaella Casanova C, Cisnal Monsalve JM, Pastor Sempere F: [Studer-type orthotopic urinary bladder: our experience]. Arch Esp Urol; 2000 Dec;53(10):893-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Studer-type orthotopic urinary bladder: our experience].
  • OBJECTIVE: To analyze the outcome, complications and functional results in patients undergoing bladder substitution with the Studer continent urinary pouch.
  • METHODS: The clinical records of 6 male patients who underwent radical cystectomy for invasive bladder cancer and bladder substitution with the Studer reservoir at our hospital from January 1996 to February 2000 were reviewed.
  • RESULTS: Transitional cell carcinoma was found to be the most frequent histopathological type.
  • Distribution by grade and pathological stage showed they were all high grade infiltrating tumors localized to the bladder.
  • Four patients are free of disease, one died from metastatic disease and one patient with tumor progression and multiple lung metastases at two months' follow-up is currently on chemotherapy.
  • The mean operating time was significantly longer for this procedure than for the non-continent Bricker urinary diversion (mean 7.2 hours vs 3.5 hours, respectively).
  • [MeSH-major] Carcinoma / surgery. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent
  • [MeSH-minor] Follow-Up Studies. Humans. Male. Middle Aged. Urinary Diversion / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11213393.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


14. Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A, Têtu B, Lacombe L, Fradet Y: Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. Eur Urol; 2009 Jun;55(6):1386-95
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
  • BACKGROUND: The clinical significance of tumor-infiltrating dendritic cells (TIDCs) and tumor-associated macrophages (TAMs) as markers of immune response has been reported for many cancers.
  • OBJECTIVE: To measure tumor infiltration by CD83(+) dendritic cells (DCs) and CD68(+) macrophages in non-muscle-invasive urothelial cancer (NMIUC) prior to bacillus Calmette-Guérin (BCG) immunotherapy and to evaluate their significance in the response to immunotherapy.
  • MEASUREMENTS: Immunohistochemical staining with anti-CD83 and anti-CD68 monoclonal antibodies on 53 and 46 NMIUC tumors, respectively, prior to BCG treatment.
  • Multivariate Cox regression analysis showed that maintenance BCG (more than one maintenance cycle) was highly effective in patients with a low level of CD83(+) TIDCs at time of resection (hazard ratio [HR]: 0.035; p=0.002) but showed reduced efficacy in patients with a high level of CD83(+) TIDCs (HR: 0.87; p=0.810).
  • If confirmed in larger cohorts, the pretreatment level of infiltration by these cells may be useful to influence the choice of treatment strategy.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. BCG Vaccine / therapeutic use. Biomarkers, Tumor / analysis. Carcinoma, Transitional Cell / drug therapy. Dendritic Cells / immunology. Macrophages / immunology. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Biopsy, Needle. Cohort Studies. Cystectomy / methods. Female. Humans. Immunohistochemistry. Immunotherapy / methods. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Predictive Value of Tests. Probability. Prognosis. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2009 Jun;55(6):1395-6 [19193488.001]
  • (PMID = 19193487.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / BCG Vaccine; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human
  •  go-up   go-down


15. Damyanov C, Tsingilev B, Tabakov V, Simeonov R: Organ-sparing treatment of invasive transitional cell bladder carcinoma. J BUON; 2002 Jul-Sep;7(3):241-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ-sparing treatment of invasive transitional cell bladder carcinoma.
  • PURPOSE: To assess the effectiveness of two approaches of organ-sparing treatment in patients with invasive transitional cell bladder carcinoma.
  • PATIENTS AND METHODS: During the period from June 1996 to June 2000, 33 patients with invasive transitional cell carcinoma (T2-4) of the bladder were treated.
  • Group A included 17 patients treated with CMV systemic chemotherapy (methotrexate 30 mg/m(2) and vinblastine 3 mg/m(2), day 1; and cisplatin 70 mg/ m(2), day 2) repeated every 3 weeks for 3 courses, combined with intravesical BCG.
  • Complete responders (CR) received maintenance intravesical BCG, while partial responders (PR) were subjected to transurethral bladder resection (TURB) or partial bladder resection.
  • After completing the 2nd chemotherapy course, 2 patients refused further treatment and were excluded from the group.
  • On completing chemoimmunotherapy 11 (73%) patients showed objective response (CR+PR) and preservation of the bladder was achieved.
  • Four (27%) patients were treatment failures.
  • On completing treatment 12 of 16 (75%) patients showed an objective response with preservation of the bladder.
  • Treatment failure was diagnosed in 4 (25%) patients.
  • CONCLUSION: The applied 2 approaches of combined organ-sparing treatment of invasive bladder carcinoma seem equally effective.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17918795.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


16. Vázquez-Lavista LG, Flores-Balcázar CH, Llorente L: [The bacillus Calmette-Guérin as immunomodulator in bladder cancer]. Rev Invest Clin; 2007 Mar-Apr;59(2):146-52
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The bacillus Calmette-Guérin as immunomodulator in bladder cancer].
  • The bacillus Calmette-Guérin (BCG) is regarded as the most successful immunotherapy against superficial bladder carcinoma recurrences to date.
  • BCG intravesical therapy for superficial bladder cancer has shown its efficacy and advantage over classical therapeutic strategies.
  • The initial step is the binding of mycobacteria to the urothelial lining, which depends on the interaction of a fibronectin attachment protein on the bacteria surface with fibronectin in the bladder wall.
  • Granulocytes and other immunocompetent mononuclear cells became attracted to the bladder wall and a cascade of proinflammatory cytokines sustains the immune response.
  • In the bladder wall a largely TH1 based cytokine milieu and granuloma-like cellular foci are established.
  • Current treatment consists of an induction phase of 6 weeks and a maintenance dose schedule of 3 weeks every three months up to 36.
  • The majority of patients present adverse events related to dose administration due to bladder inflammatory response and on only a few occasions, there are mayor complications like granulomatous prostatitis.
  • Among all the neoplasms only in superficial bladder cancer the BCG is proved to be effective.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. BCG Vaccine / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Bacterial Adhesion. Cystitis / etiology. Cytotoxicity, Immunologic. Female. Humans. Killer Cells, Natural / immunology. Lymphocytes, Tumor-Infiltrating / immunology. Lymphokines / secretion. Male. Models, Immunological. Mycobacterium bovis. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / therapy. Prostatitis / etiology. Th1 Cells / secretion

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633803.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine; 0 / Lymphokines
  • [Number-of-references] 42
  •  go-up   go-down


17. Karamitopoulou E, Rentsch CA, Markwalder R, Vallan C, Thalmann GN, Brunner T: Prognostic significance of apoptotic cell death in bladder cancer: a tissue microarray study on 179 urothelial carcinomas from cystectomy specimens. Pathology; 2010 Jan;42(1):37-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of apoptotic cell death in bladder cancer: a tissue microarray study on 179 urothelial carcinomas from cystectomy specimens.
  • AIMS: To assess the prognostic significance of apoptosis related markers in bladder cancer.
  • METHODS: A tissue microarray containing 179 bladder carcinomas from cystectomy specimens was analysed immunohistochemically for active caspase-3, single-stranded DNA (ssDNA), p53, Bcl-2, Bax, and COX-2, in correlation to clinicopathological factors.
  • CONCLUSIONS: The decreased detection of active caspase-3 and ssDNA and the increased presence of Bcl-2 in T1 carcinomas suggest that alterations in interrelated apoptosis markers may play an important role in the progression of urothelial carcinoma from a superficially infiltrating to a muscle invading tumour and would help to better characterise a subpopulation of T1 carcinomas that could profit from early cystectomy or more aggressive adjuvant chemotherapy.
  • Active caspase-3 might be an important prognostic factor in bladder cancer.
  • [MeSH-major] Apoptosis. Carcinoma, Transitional Cell / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Caspase 3 / metabolism. Cystectomy. DNA Fragmentation. DNA, Neoplasm. DNA, Single-Stranded. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Survival Rate. Tissue Array Analysis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20025478.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / DNA, Single-Stranded; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


18. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI: Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol; 2007 Aug;31(8):1246-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
  • The histologic distinction between high-grade prostate cancer and infiltrating high-grade urothelial cancer may be difficult, and has significant implications because each disease may be treated very differently (ie, hormone therapy for prostate cancer and chemotherapy for urothelial cancer).
  • Immunohistochemistry of novel and established prostatic and urothelial markers using tissue microarrays (TMAs) were studied.
  • "Urothelial markers" included high molecular weight cytokeratin (HMWCK), p63, thrombomodulin, and S100P (placental S100).
  • TMAs contained 38 poorly differentiated prostate cancers [Gleason score 8 (n=2), Gleason score 9 (n=18), Gleason score 10 (n=18)] and 35 high-grade invasive urothelial carcinomas from radical prostatectomy and cystectomy specimens, respectively.
  • Each case had 2 to 8 tissue spots (0.6-mm diameter).
  • Because of PSA's high sensitivity on the TMA, we chose 41 additional poorly differentiated primary (N=36) and metastatic (N=5) prostate carcinomas which showed variable PSA staining at the time of diagnosis and performed immunohistochemistry on routine tissue sections.
  • HMWCK, p63, thrombomodulin, and S100P showed lower sensitivities in labeling high-grade invasive urothelial cancer in the TMAs with 91.4%, 82.9%, 68.6%, and 71.4% staining, respectively.
  • These urothelial markers were relatively specific with only a few prostate cancers showing scattered (<or=2%) weak-moderate positive cells.
  • In summary, PSA can be used as the first screening marker for differentiating high-grade prostate adenocarcinoma from high-grade urothelial carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Carcinoma, Transitional Cell / secondary. Immunoenzyme Techniques / methods. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Predictive Value of Tests. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667550.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


19. Huguet J, Gaya JM, Sabaté S, Palou J, Villavicencio H: [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy]. Actas Urol Esp; 2010 Jan;34(1):63-70
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy].
  • [Transliterated title] Cistectomía radical en tumores vesicales no músculoinfiltrantes que fracasan al tratamiento con bacilo de Calmette-Guérin.
  • OBJECTIVE: To assess the characteristics and outcomes of patients with non-muscle invasive bladder cancer (NMIBC) undergoing radical cystectomy (RC) due to BCG failure.
  • MATERIALS AND METHODS: Ninety-five (11%) of the 864 patients undergoing radical cystectomy (RC) at our center from 1989 to 2002 had received prior treatment with BCG.
  • Of these, 62 (65.2%) underwent RC due to relapsing, high-risk NMIBC or CIS despite BCG therapy.
  • Their last transurethral resection before RC showed invasive disease.
  • RESULTS: Five-year CSS was 90% in 45 patients with clinical and pathological NMIBC and 50.6% in 50 patients with progression to muscle-infiltrating disease (clinical progression and understaged) (p < 0,05).
  • Median time from tumor diagnosis to tumor progression was 24 months (10th-90th percentile, 6-98 months).
  • CONCLUSION: In patients with high-risk NMIBCs who fail BCG therapy, RC should be performed before progression because survival is decreased when the RC specimen shows muscle-invasive disease.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. BCG Vaccine / therapeutic use. Biopsy. Disease Progression. Drug Resistance, Neoplasm. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Treatment Outcome. Urethra / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223134.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


20. Smaldone MC, Jacobs BL, Smaldone AM, Hrebinko RL Jr: Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. Urology; 2008 Sep;72(3):613-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma.
  • METHODS: From 1995 to 2005, 25 patients with urothelial carcinoma underwent partial cystectomy with curative intent.
  • As protocol, patients with primary solitary muscle-invasive bladder tumors underwent preoperative localized radiotherapy, administration of a single dose of intravesical chemotherapy at the time of partial cystectomy, and postoperative intravesical Bacillus Calmette-Guérin therapy.
  • At time of transurethral resection of a bladder tumor (TURBT), all had a solitary primary T2 (68%) or T1HG (32%) lesion with no evidence of carcinoma in situ.
  • At a mean of 18.0 +/- 15.6 months, 8% of patients experienced intravesical non-muscle-invasive tumor recurrences and were treated with TURBT and intravesical chemotherapy.
  • Twenty percent recurred with locally advanced tumors or visceral metastasis and were treated with systemic chemotherapy, local resection or cystectomy, or both.
  • On univariate analysis, only tumor size at time of partial cystectomy (P = .03) was significantly associated with tumor recurrence.
  • CONCLUSIONS: Partial cystectomy offers adequate control of localized invasive urothelial carcinoma in carefully selected patients with solitary primary tumors.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Urinary Bladder Neoplasms / surgery. Urothelium / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. BCG Vaccine / therapeutic use. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Recurrence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18554696.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCG Vaccine
  •  go-up   go-down


21. Gogna NK, Matthews JH, Turner SL, Mameghan H, Duchesne GM, Spry N, Berry MP, Keller J, Tripcony L, Trans Tasman Radiation Oncology Group: Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. Radiother Oncol; 2006 Oct;81(1):9-17
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
  • BACKGROUND AND PURPOSE: To determine the feasibility, toxicity, and clinical effectiveness of concurrent weekly cisplatin chemotherapy in conjunction with definitive radiation in the treatment of localised muscle invasive bladder cancer.
  • PATIENTS AND METHODS: In January 1997 the Trans Tasman Radiation Oncology Group embarked on a Phase II study (TROG 97.01) of weekly cisplatin (35 mg/m(2) x 7 doses) plus radiation to a dose of 63 Gy over 7 weeks.
  • Following an interim toxicity analysis, the dose intensity of cisplatin was reduced to 6 cycles and the radiation schedule changed to 64 Gy over 6.5 weeks leading to the second study (TROG 99.06).
  • RESULTS: Acute grade 3 urinary toxicity occurred in 23% of the patients.
  • Local invasive recurrence was seen in 11 of the 79 patients (14%).
  • The local control rate was 45% with a functional bladder being retained in 69 of the 113 patients (61%).
  • CONCLUSION: Our two sequential Phase II studies have shown that concurrent chemoradiation using weekly cisplatin in the management of localised invasive bladder TCC is feasible and reasonably well tolerated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / radiotherapy. Cisplatin / therapeutic use. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy / methods. Cystectomy. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Radiation-Sensitizing Agents / adverse effects. Radiation-Sensitizing Agents / therapeutic use. Remission Induction. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Radiother Oncol. 2007 May;83(2):215. Mameghan, Heidi [corrected to Mameghan, Hedy]
  • (PMID = 17011058.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement